


# Pacific Focus China Fund

## Investment objective

The Fund aims to achieve attractive capital growth in the medium to long term by investing predominantly in equities and equity-related securities of companies listed in the greater China region which covers China, Hong Kong S.A.R. and Taiwan markets and may invest in companies listed in other markets that have significant or potentially significant business in the greater China region.




## Performance

	1 Mth	6 Mths	1 Yr	3 Yrs	5 Yrs	Since Launch <sup>▲</sup>
<b>Fund*</b>	2.80%	16.43%	25.18%	17.29%	58.73%	113.14%
<b>Benchmark#</b>	3.60%	18.36%	29.43%	18.38%	64.87%	134.21%

\* Source: Lipper for Investment Management, 31 August 2020. Fund sector: Equity Greater China

# Benchmark: MSCI Golden Dragon Index (MXGD), source: Bloomberg, 31 August 2020. Return of benchmark, which are indices that track foreign markets, have been adjusted by the movement of the Malaysian Ringgit (MYR) against the foreign currencies.

▲ Since start investing date: 12 June 2009



## Asset allocation

<b>Equities</b>	94.54%
<b>Cash</b>	5.46%

## Country allocation

<b>Hong Kong</b>	61.93%	<b>US</b>	16.41%
<b>Taiwan</b>	20.44%	<b>Malaysia</b>	1.22%

## Fund details

<b>Characteristic</b>	Aggressive
<b>Fund category/type</b>	Equity / Growth
<b>Launch date</b>	19 May 2009
<b>Financial year end</b>	31 March
<b>Fund size</b>	RM16.5 million (as at 28 August 2020)
<b>NAV per unit</b>	RM0.3813 (as at 28 August 2020)
<b>Highest/Lowest NAV per unit (for current financial year)</b>	Highest 28 Aug 2020 RM0.3813 Lowest 19 Mar 2020 RM0.2967
<b>Income distribution</b>	Once a year, if any.
<b>Sales charge</b>	Up to 5.50% of the Fund's NAV per unit
<b>Annual management fee</b>	Up to 1.60% p.a. of the NAV of the Fund
<b>Fund manager (external)</b>	Lion Global Investors Limited (formerly known as Lion Capital Management Limited)
<b>Sales office</b>	BOS Wealth Management Malaysia Berhad (formerly known as Pacific Mutual Fund Bhd) 199501006861 (336059-U) <a href="mailto:customercare@boswm.com">customercare@boswm.com</a>

+ Volatility Factor (VF) as at 31 July 2020: 16.3. Volatility Class (VC) as at 30 June 2020: Very High (above 15.4). VF means there is a possibility for the Fund in generating an upside return or downside return around this VF. VC is assigned by Lipper based on quintile ranks of VF for qualified funds. VF is subject to monthly revision and VC is revised every six months. The Fund's portfolio may have changed since this date and there is no guarantee that the Fund will continue to have the same VF or VC in the future. Presently, only funds launched in the market for at least 36 months will display the VF and its VC. Source: Lipper.

## Equities – Sector exposure & Top 10 holdings

<b>RETAILING</b>	14.34%	<b>TENCENT HOLDINGS LIMITED (HK)</b>	10.22%
<b>SEMICONDUCTORS &amp; SEMI. EQUIPMENT</b>	14.26%	<b>ALIBABA GROUP HOLDING LIMITED (US)</b>	10.06%
<b>MEDIA &amp; ENTERTAINMENT</b>	11.76%	<b>TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW)</b>	9.45%
<b>INSURANCE</b>	7.39%	<b>AIA GROUP LIMITED (HK)</b>	4.63%
<b>BANKS</b>	6.60%	<b>CHINAAMC CSI 300 INDEX ETF (HK)</b>	4.47%
<b>PHARMA., BIOTECH. &amp; LIFE SCIENCES</b>	5.46%	<b>WUXI BIOLOGICS (CAYMAN) INC. (HK)</b>	3.95%
<b>EXCHANGE TRADED FUND</b>	4.47%	<b>CHINA CONSTRUCTION BANK CORPORATION (HK)</b>	3.76%
<b>DIVERSIFIED FINANCIALS</b>	4.09%	<b>JD.COM, INC. (HK)</b>	2.46%
<b>REAL ESTATE</b>	3.61%	<b>HONG KONG EXCHANGES &amp; CLEARING LIMITED (HK)</b>	2.11%
<b>MATERIALS</b>	3.15%	<b>CHINA LIFE INSURANCE COMPANY LTD. (HK)</b>	1.91%

## Income distribution (past 10 years)

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<b>Gross distribution (sen)</b>	-	-	-	-	-	2.00	2.50	2.50	2.50	1.75
<b>Distribution yield (%)</b>	-	-	-	-	-	6.65	6.74	6.56	6.95	5.46

### Markets & Fund Commentary

For the month of August 2020, MSCI Hong Kong and MSCI China outperformed while MSCI Taiwan underperformed the overall MSCI Golden Dragon Index.

Asian markets rallied in August 2020, aided by a weak dollar, abundant liquidity, hopes of economic activity picking up and continued support from government stimulus. After a strong tech-driven rally in the Taiwan market in July 2020, it gave back some of its gains in August 2020. Hong Kong market clawed back some of its earlier weakness due to the National Security Law imposition on 30 June 2020, as it benefited from China market's continued exuberance on strong macro numbers e.g. 2Q 2020 GDP growth of 3.2% versus -6.8% contraction in 1Q 2020. Investment and industrial production have recovered, while consumption is still lagging.

During the month, the biggest contributor to performance was Wuxi Biologics driven by its strong 1H 2020 results and order backlog growth, while the largest detractor was our underweight in Meituan Dianping, whose share price benefited from strong 1H 2020 results and its market-share gain despite COVID-19 challenges.

With much of the economic activity in Greater China returning close to normal levels, except travel, the outlook for the second half should be one of continued recovery, albeit at a slower pace sequentially versus 2Q 2020. However, the risk of some resurgence in COVID-19 cases cannot be ruled out; hence the rebound may also be choppy. We also expect US-China tensions to remain in the headlines ahead of the US elections in November 2020. This could create more volatility for technology and other sectors that are dependent on the US, but over the longer term, this will accelerate China's push for greater self-sufficiency in key technologies and supply chains. Key risks to the markets are geopolitics, uncertain recovery pace and potential for second wave of infections.

### Disclaimer

This publication has not been reviewed by the Securities Commission of Malaysia (SC). This leaflet provides general information and does not have regard to any specific investment objective, financial situation or particular personal need. The fund performance is calculated on an NAV-NAV basis including any capital gains and reinvested income distributions. Replacement master prospectus dated 1 April 2019 with its supplementary replacement master prospectus dated 22 July 2019 and Product Highlights Sheet ("PHS") are obtainable at our offices and you have the right to request for a copy. They have been registered and lodged with the SC (where applicable), who takes no responsibility for their contents. The registration and lodgement does not amount to nor indicate that the SC has recommended or endorsed the fund. Units will only be issued when we receive the official account application form and investment form. You should study the prospectuses and PHS, and consider the fees and charges involved before investing. You should also note that distributions and net asset value per unit do go up and down. Past performance is not an indication of future performance. The specific risk of Pacific Focus China Fund is country and/or foreign securities risk. Description of the specific risk can be obtained from the replacement master prospectus dated 1 April 2019. Where a distribution is declared, you are advised that following the distribution, the NAV per unit will be reduced from cum-distribution NAV to ex-distribution NAV.